What is CAI's five-year median P/E?

16.8x. Half of CAI's weekly readings since August 2026 were higher and half were lower. This page has 26 weekly readings, from May 4, 2026 to Oct 26, 2026.

Does a low historical rank mean a stock is a buy?

No. The rank compares CAI only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.

Caris Life Sciences Inc (CAI) valuation history

Health Care

$35.82

Latest weekly close · Market cap $10.1B

Caris Life Sciences' P/E of 21.2x has weekly readings only since August 2026, not enough history to rank yet, but its recent earnings include a large one-time loss outside its main business. Its P/S is higher than 98% of its weekly readings since May 2026 (as of Oct 29, 2026).

Forward P/E 96.3× (analyst estimates, not ranked).

Weekly P/E since August 2026

P/E each weekMiddle half of its readingsMedian 16.8×

Median: 16.8×
Low to high: 12.9× to 21.2×
Versus median: +27%
History starts: August 2026

P/E

n/mnot ranked

P/E needs more weekly history to be ranked.

Growth, last 12 months vs the year before

Revenue: +85%
EPS: n/m

Price vs revenue and EPS, indexed to 100

Each line starts at 100 at its first positive reading over the last five years. Revenue and EPS change at fiscal quarter ends.

PriceRevenue, last 12 monthsEPS, last 12 months100 = first reading

P/E at each year-end

The last weekly reading of each year, and its percentile against the five years before it.

No full calendar year of readings yet.

Health Care peers on P/E

Each percentile compares a stock with its own last five years.

Compare CAI with peers

Health Care peers of CAI on P/E
Stock	P/E	Versus its own history	5-year percentile
ABBVAbbVie	80.8×	Above its usual range	76
AMGNAmgen	28.1×	Above its usual range	80
ARWRArrowhead Pharmaceuticals Inc	n/m	Not ranked	n/m, not ranked
BBIOBridgebio Pharma Inc	n/m	Not ranked	n/m, not ranked
BIIBBiogen	105.2×	Historically high	100

Appears in

Sector: Health Care
Screens: Nuclear Stocks: Valuation Screen
Semiconductor Equipment Stocks: Valuation Screen

Screen Health Care stocks the same way

Research on CAI

No articles about CAI yet. How valuation percentiles work

Loading peers and related research…

About this history

What is CAI's current P/E?: Caris Life Sciences' P/E of 21.2x has weekly readings only since August 2026, not enough history to rank yet, but its recent earnings include a large one-time loss outside its main business. Its P/S is higher than 98% of its weekly readings since May 2026 (as of Oct 29, 2026).
What is CAI's five-year median P/E?: 16.8x. Half of CAI's weekly readings since August 2026 were higher and half were lower. This page has 26 weekly readings, from May 4, 2026 to Oct 26, 2026.
Does a low historical rank mean a stock is a buy?: No. The rank compares CAI only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.